Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

Market Cap	9.07B
Revenue (ttm)	16.16B
Net Income (ttm)	545.17M
Shares Out	2.52B
EPS (ttm)	0.21
PE Ratio	17.09
Forward PE	13.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,820,362
Average Volume	28,382,025
Open	3.600
Previous Close	3.600
Day's Range	3.550 - 3.610
52-Week Range	3.060 - 4.970
Beta	0.17
RSI	36.06
Earnings Date	Oct 28, 2025

About SHA:600664

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 10,180
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600664

Financial Performance

In 2024, SHA:600664's revenue was 16.18 billion, an increase of 4.65% compared to the previous year's 15.46 billion. Earnings were 628.85 million, an increase of 59.10%.